hexylresorcinol has been researched along with Cancer of Mouth in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "4‑Hexylresorcinol (4HR) is a pharmacologic chaperone." | 1.72 | Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation. ( Chae, WS; Kang, YJ; Kim, DW; Kim, SG; Rotaru, H; Yang, WG, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, YJ | 1 |
| Yang, WG | 1 |
| Chae, WS | 1 |
| Kim, DW | 1 |
| Kim, SG | 3 |
| Rotaru, H | 2 |
| Lee, SW | 1 |
| Park, YW | 1 |
| Kweon, H | 1 |
| Kim, JY | 1 |
| Choi, JY | 1 |
3 other studies available for hexylresorcinol and Cancer of Mouth
| Article | Year |
|---|---|
Administration of 4‑hexylresorcinol increases p53‑mediated transcriptional activity in oral cancer cells with the p53 mutation.
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; DNA; Hexylresorcinol; Humans; Mouth Neoplasms; Mutation; Pro | 2022 |
Cisplatin and 4-hexylresorcinol synergise to decrease metastasis and increase survival rate in an oral mucosal melanoma xenograft model: a preliminary study.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopt | 2013 |
4-hexylresorcinol exerts antitumor effects via suppression of calcium oscillation and its antitumor effects are inhibited by calcium channel blockers.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Calcium Channel Blockers; Calcium Signaling; | 2013 |